Scott Q. Siler, Ph.D.
Chief Science Officer
DILIsym Services Division
Scott Q Siler, Ph.D. is the Chief Scientific Officer of the DILIsym Services division of Simulations Plus. Dr. Siler leads the quantitative systems pharmacology (QSP) and toxicology (QST) efforts within Simulations Plus. On the QSP front, Dr. Siler has led the development and application of NAFLDsym, which has been used to evaluate >25 non-alcoholic steatohepatitis (NASH) compounds and/or targets to date. He has also led the development and application of IPFsym, a QSP model of idiopathic pulmonary fibrosis (IPF), which has been used to evaluate >10 compounds and/or targets to date. Dr. Siler has also led the de novo development of several focused QSP model development efforts to support the development of specific assets across a variety of therapeutic areas for several pharma companies. On the QST side, Scott has led and contributed to the development of DILIsym. DILIsym has been used to evaluate the risk for drug-induced liver injury (DILI) of >80 compounds to date and is arguably the most successful QST model available for use.
Prior to joining DILIsym Services and Simulations Plus, Dr. Siler worked for more than 12 years integrating physiology and mathematics with Entelos, a provider of in silico modeling and simulation products and consulting services. Dr. Siler managed and contributed to the development of the Metabolism PhysioLab during that time. Additionally, while at Entelos, he led multiple projects evaluating potential treatments for type 2 diabetes.
Dr. Siler graduated with a Ph.D. in Nutrition from the University of California, Berkeley, and a bachelor of arts in biochemistry and molecular biology from the University of California, Santa Cruz.